上海盟科药业股份有限公司2025年年度业绩预告

Group 1 - The company forecasts an annual revenue of approximately 135 million to 155 million yuan for 2025, representing an increase of 4.73 million to 24.73 million yuan compared to the previous year, with a year-on-year growth of 3.63% to 18.98% [1] - The projected net profit attributable to the parent company for 2025 is expected to be between -265 million to -225 million yuan, indicating a reduction in losses by 175.72 million to 215.72 million yuan compared to the previous year, with a year-on-year decrease in losses of 39.87% to 48.95% [1] - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -274 million to -234 million yuan, reflecting a decrease in losses by 185.17 million to 225.17 million yuan compared to the previous year, with a year-on-year reduction in losses of 40.33% to 49.04% [1] Group 2 - The previous year's revenue was 130.27 million yuan [2] - The total profit for the previous year was -434.51 million yuan, with a net profit attributable to shareholders of -440.72 million yuan and a net profit after deducting non-recurring gains and losses of -459.17 million yuan [3] - The earnings per share for the previous year was -0.67 yuan [4] Group 3 - The company achieved a slight increase in revenue year-on-year during the reporting period, while also managing to reduce overall costs and expenses compared to the previous year through improved management of sales, research and development, and organizational structure [5]